logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

Angiogenic factors

imatge Central Grup Recerca

Scientific Team

Researchers
Francesc Viñals
Collaborators
Agnes Figueras
Predoctoral researchers
Elisenda Alsina, Alicia Mansilla
Master and grade students
Zachary chanell Croes, Carla Riera

Introduction

The overall objective of the subgroup is studying how different angiogenic factors (TGF-beta, VEGF and EGF) modulate angiogenesis process both in physiological and tumoral context. We study the effect of these factors activating receptors in endothelial cells, stimulating different signaling pathways and regulating important genes in angiogenesis. At tumour level, we focused on testicular/ovarian germ cell cancer, studying new anti-TGF-beta, anti-angiogenic and anti-EGF therapies, its effect on the cancer stem cells of this tumour, as well as the presence of circulating markers of tumour progression.


Research group

Tumour Angiogenesis

Research lines

. Mechanisms involved in the pro-angiogenic effect of TGF-beta, the EGF and VEGF.

 

. Metronomic administration of chemotherapeutic agents as antiangiogenic therapy

 

. Investigation of noninvasive biomarkers in clinical trials with antiangiogenic

 

. Mechanisms of resistance and invasion in response to antiangiogenic therapies in animal models and in human tumors

 

. Signaling pathways in angiogenesis


Group publications

 

W. Castillo-Ávila, J.M. Piulats, X. Garcia del Muro, A. Vidal, E. Condom, O. Casanovas, J. Mora, J.R. Germà, G. Capellà, A. Villanueva & F. Viñals. “Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and resistant human testicular germ cell tumors”. Clinical Cancer Research 15: 3384-95, 2009.

 

B. del Valle-Pérez, V.G. Martínez, C. Lacasa-Salavert, A. Figueras, S.S. Shapiro, T. Takafuta, O. Casanovas, G. Capellà, .F. Ventura & F. Viñals. “Filamin B plays a key role in VEGF-induced endothelial cell motility through its interaction with Rac-1 and Vav-2”. Journal of Biological Chemistry 285: 10748-60, 2010.

 

 

Collaborations

 

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D & Casanovas O. “Anti-angiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis”. Cancer Cell 15: 220-31, 2009.

 

J.M. Piulats, L. Jiménez, X. Garcia del Muro, A. Villanueva, F. Viñals & J.R. Germà-Lluch. “Molecular mechanisms behind the resistance of cisplatin in germ cell tumours”. Clinical Translational Oncology 11: 780-6, 2009.

 

A. Urruticoechea, R. Alemany, J. Balart, A. Villanueva, F. Viñals & G. Capellà. “Recent advances in cancer therapy: An overview”. Current Pharmaceutical Design 16: 3-10, 2010.

 

O. Casanovas, F. Viñals & B. Jiménez. “Angiogenesis: Molecular Basis” in Present and Future for antiangiogenic therapies in cancer. International Oncology Updates, Ed. Hernán Cortés-Funes, 1-19, 2010.

Project: Hipoxia, fenotipo glicolítico y angiogenesis tumoral, Grupo miembro de la Red Temática de Investigación Cooperativa en Cáncer (RTICC)  RD2006-0092

Financing entity: Insituto de Salud Carlos III, Ministerio de Sanidad y Consumo.

Partners: IDIBELL

Term,  desde: 2007 hasta: 2010

Coordinator: Francesc Ventura (Coordinador)

IP number: 33

 

Project: Nuevos mecanismos implicados en la angiogénesis fisiológica y tumoral.

Financing entity: DGICYT Ref SAF2007-60955.

Partners: IDIBELL

Term,  desde: 2008 hasta: 2010

Amount: 160.000 euros

Coordinator: Francesc Viñals Canals

IP number: 4

 

Project: Estudio de los patrones clínicos y biológicos asociados a la progresión tumoral en pacientes con cáncer de colon en tratamiento con fármacos antiangiogénicos.

Financing entity: Proyecto de Investigación Clínica no comercial con medicamentos de uso humano. Insituto de Salud Carlos III, Ministerio de Sanidad y Consumo. EC08/00097

Partners: IDIBELL (ICO)

Term,  desde: 2009 hasta: 2010

Amount: 51.062 euros

Coordinator: Margarita García Martín

 

Project: GENÉTICA, TERAPIA Y ANGIOGÉNESIS DE TUMORES COLORECTALES, PANCREÁTICOS  Y GERMINALES.

Financing entity: Ayuda para Grupos Consolidados 2009, 2009SGR283. Generalitat de Catalunya.

Partners: IDIBELL

Term,  desde: 2009 hasta: 2013                 

Amount:45.760 euros

Coordinator: Francesc Viñals Canals

IP number: 24

 

Project: BASES MOLECULARES DEL EFECTO PRO-ANGIOGÉNICO DEL TGFb EN MODELOS FISIOLÓGICOS Y TUMORALES

Financing entity: DGICYT Ref SAF2010-20859

Partners: IDIBELL

Term,  desde: 2011 hasta: 2013

Amount:160.000 euros

Coordinator: Francesc Viñals Canals

IP number: 4

imatge personal
 

Subgroup head (PI)

Francesc Viñals
Telephone  
+34 932607344
E-mail  
fvinyals@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell